Loyal is a pioneering clinical-stage veterinary medicine company focused on developing innovative drugs aimed at extending the lifespan and healthspan of dogs. With a mission to enhance the quality of life for dogs, Loyal has made significant strides towards obtaining FDA approval for the first lifespan extension drug for any species, with three products currently in its pipeline and plans to launch the first product by 2025. As a well-funded startup in growth mode, Loyal's diverse team comprises scientists, veterinarians, engineers, operators, and creatives, all dedicated to advancing veterinary medicine and improving the lives of pets.